Peptron (087010.KQ) Stock Price

Peptron, Inc. generates revenue through the development and sale of peptide-based medicines and novel drugs, primarily targeting prostate cancer, hyperpituitarism, diabetes, and neurodegenerative disorders. The company produces peptides as drug materials, offers peptide synthesis services, and manufactures raw material medicines and functional cosmetics. Its products are distributed domestically and internationally, serving healthcare providers and pharmaceutical companies seeking peptide-based solutions for these specific medical conditions. Peptron's primary revenue streams include the sale of peptide-based drug materials, synthesis services for pharmaceutical clients, and the distribution of raw material medicines and functional cosmetics. The company focuses on markets requiring treatments for prostate cancer, hyperpituitarism, diabetes, and neurodegenerative disorders, with a domestic presence and international distribution channels. Its product portfolio targets both medical and cosmetic applications through peptide technology. The firm's business model relies on direct sales of its peptide-based medicines and synthesis services to pharmaceutical companies and healthcare institutions. By manufacturing raw material medicines and functional cosmetics, Peptron diversifies its revenue sources beyond traditional pharmaceuticals, catering to both medical and consumer markets. Its domestic and overseas distribution network supports the commercialization of products for specific therapeutic areas and cosmetic uses.